Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.45 |
| ▸ | CA2 | P00918 | 12/20 | 0.45 |
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17593112 | 1.00 | CA1 (0.45) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL17592707 | 0.84 | PTGDR2 (0.52) | FFAR4KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL17592706 | 0.84 | PTGDR2 (0.52) | FFAR4KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL17593056 | 0.83 | MEN1 (0.41) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL17593054 | 0.83 | MEN1 (0.41) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL17592714 | 0.80 | LSS (0.48) | FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL17593115 | 0.80 | LSS (0.48) | FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL17592713 | 0.80 | LSS (0.48) | FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL19321721 | 0.80 | LSS (0.48) | FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL19321718 | 0.80 | LSS (0.48) | FFAR4KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191454-B1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9938222-B2 | Cyclopropanecarboxylic acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170253554-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-07 | — | — | US | disclosed |
| EP-3191454-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040222-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253554-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPBAR1, GPR68 | CA1 2808/4885CA2 521/4885CA9 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.